Study guide
11.2 Drug-Induced Disease and Drug Use Disorders
NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the FPGEE 1.2 How to Use This Study Guide
2 Chapter 2: Foundational Biomedical Sciences I
2.1 Anatomy 2.2 Physiology 2.3 Biochemistry
3 Chapter 3: Foundational Biomedical Sciences II
3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases
4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry
4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions
5 Chapter 5: Pharmacology and Toxicology
5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes
6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics
6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics
7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems
7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics
8 Chapter 8: Public Health, Practice Management, and Biostatistics
8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods
9 Chapter 9: Professional Communication and Behavioral Aspects
9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice
10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment
10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education
11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care
11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine
12 Chapter 12: Clinical Sciences III — Evidence-Based Practice
12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability
13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products
13.1 Self-Care and Natural Products
11.2 Drug-Induced Disease and Drug Use Disorders
Key Takeaways Explain This Topic AI
Drug-induced liver injury (DILI) patterns are hepatocellular (acetaminophen, isoniazid), cholestatic (amoxicillin-clavulanate, anabolic steroids), or mixed (phenytoin, sulfonamides); Hy's law (ALT ≥3×ULN with bilirubin ≥2×ULN and no ALP elevation) predicts a ≥10% mortality and demands immediate drug discontinuation.
Drug-induced pulmonary, renal, hematologic, endocrine, dermatologic, and musculoskeletal diseases have signature culprit drugs — fluoroquinolones and tendinopathy, amiodarone and pulmonary fibrosis, penicillins/PPIs/NSAIDs and acute interstitial nephritis, sulfonamides/allopurinol/anticonvulsants and SJS/TEN.
Opioid use disorder is diagnosed by DSM-5 criteria and treated with medications for addiction treatment (MAT) — buprenorphine (partial agonist), methadone (full agonist, OTP-only for OUD), and naltrexone (antagonist) — combined with counseling and naloxone access for overdose reversal.
Tobacco use disorder has three first-line pharmacotherapies — nicotine replacement therapy (NRT), varenicline (α4β2 partial agonist), and bupropion (NET/DAT inhibitor); varenicline is generally most effective as monotherapy.
Harm reduction — needle/syringe exchange, supervised consumption sites, fentanyl test strips, naloxone distribution — reduces infectious and overdose mortality without increasing drug use, and pharmacists engage via PDMP review, REMS compliance, and identification of misuse, abuse, diversion, and pseudoaddiction.
Last updated: July 2026
11.2 Drug-Induced Disease and Drug Use Disorders
Quick Answer: Drug-induced diseases have signature culprit drugs by organ system — DILI patterns (Hy's law) , amiodarone pulmonary toxicity , AIN from penicillins/PPIs/NSAIDs , SJS/TEN from allopurinol, sulfonamides, and anticonvulsants , fluoroquinolone tendinopathy . Drug use disorders (DSM-5) include opioid, sedative/hypnotic, stimulant, cannabis, and tobacco use disorders, treated with MAT (buprenorphine, methadone, naltrexone), counseling, harm reduction (naloxone, syringe exchange, fentanyl testing), and structured controls ( REMS, PDMPs ).
- Drug-Induced Diseases by Organ System
- Pulmonary Toxicity
Amiodarone pulmonary toxicity (amiodarone-induced pneumonitis or pulmonary fibrosis) is a life-threatening complication of a drug with iodine moieties and a long half-life (up to 100 days). Risk correlates with cumulative dose and duration (>6 months, >400 mg/day). Presentation includes progressive dyspnea, cough, diffuse interstitial infiltrates on imaging. Management : discontinue amiodarone, consider corticosteroids. Nitrofurantoin pneumonitis (acute or chronic) presents with lung infiltrates and eosinophilia; resolves with discontinuation. Methotrexate pneumonitis presents with dry cough, dyspnea, and ground-glass opacities; treat by stopping MTX and giving corticosteroids. Bleomycin causes dose-dependent pulmonary fibrosis; risk increases above 450 units cumulative and is worsened by renal impairment and oxygen exposure.
Drug-Induced Liver Injury (DILI)
DILI is classified by the R ratio (ALT/ALP ratio normalized to ULN): hepatocellular (R ≥5), cholestatic (R ≤2), or mixed (R >2 and <5). Common culprits and patterns:
Pattern Representative Drugs Notes
Hepatocellular acetaminophen, isoniazid, rifampin, statins, valproate, NSAIDs Acetaminophen dose-dependent; isoniazid idiosyncratic (warn ALT monitoring)
Cholestatic amoxicillin-clavulanate, anabolic steroids, chlorpromazine, erythromycin estolate Penicillin-clavulanate is the most common cause of DILI in many series
Mixed phenytoin, sulfonamides, azathioprine, methotrexate Phenytoin DILI often with hypersensitivity features (DRESS)
Hy's law is the most important predictor of severe DILI: ALT or AST ≥3× ULN with bilirubin ≥2× ULN (without ALP elevation indicating obstruction or other cause) and no alternative explanation. A positive Hy's law case predicts ≥10% mortality and the suspected drug must be discontinued immediately .
Renal Toxicity
Acute interstitial nephritis (AIN) is a hypersensitivity reaction presenting with fever, rash, eosinophilia, and acute kidney injury typically 7–10 days after exposure (shorter on re-exposure). Common culprits: penicillins (especially methicillin), proton pump inhibitors (PPIs), NSAIDs, cephalosporins, sulfonamides, rifampin, ciprofloxacin, allopurinol, mesalamine, 5-HMs . Treatment : discontinue the offending agent; corticosteroids for severe or persistent AKI.
Crystal nephropathy occurs when poorly soluble drugs or metabolites precipitate in renal tubules: acyclovir (especially with rapid IV push or inadequate hydration), indinavir (HIV protease inhibitor), sulfonamides (older agents), methotrexate (high dose). Hemolytic-uremic syndrome (HUS) is associated with quinine (the classic "quinine HUS") and some chemotherapeutics.
Other renal injury patterns: aminoglycoside proximal tubular toxicity (nonoliguric AKI), vancomycin (interstitial nephritis and AKI), lithium (chronic interstitial nephritis, nephrogenic DI), cyclosporine/tacrolimus (afferent arteriolar vasoconstriction), NSAIDs (afferent arteriolar vasoconstriction → AKI; can trigger AKI in volume-depleted patients).
Hematologic Toxicity
Drug-induced thrombocytopenia — heparin (HIT, an IgG antibody against PF4-heparin complex; causes paradoxical thrombosis, platelet drop ≥50% 5–14 days after exposure; discontinue all heparin and switch to argatroban or bivalirudin), quinine (quinine-induced thrombocytopenia), GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban).
Agranulocytosis — clozapine (requires REMS ANC monitoring: weekly for 6 months, then biweekly, then monthly), antithyroid drugs (methimazole, propylthiouracil — warn about sore throat and fever; check CBC), colchicine (chronic use in renal impairment), sulfasalazine , chemotherapy .
Hemolysis in G6PD deficiency — triggers include sulfonamides, primaquine, dapsone, nitrofurantoin, rasburicase, methylene blue, fava beans . Screen G6PD before prescribing high-risk drugs in at-risk populations (African, Mediterranean, Southeast Asian ancestry).
Endocrine Toxicity
Drug-induced diabetes : glucocorticoids (counter-regulatory), atypical antipsychotics (especially olanzapine and clozapine , with weight gain and insulin resistance), thiazide diuretics (mild hyperglycemia), beta blockers (mask hypoglycemia symptoms). SIADH with hyponatremia : SSRIs (especially in elderly females), carbamazepine , oxcarbazepine , vincristine , cyclophosphamide , thioridazine , chlorpropamide . Management: fluid restriction, hypertonic saline for severe symptomatic hyponatremia, demeclocycline or vaptans (rarely).
Dermatologic Toxicity
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous reactions with skin detachment (SJS <10% BSA, TEN >30% BSA, SJS-TEN overlap 10–30%). Classic culprits: allopurinol , sulfonamides (especially TMP-SMX), anticonvulsants (carbamazepine, lamotrigine, phenytoin), NSAIDs (especially oxicams), nevirapine . HLA-B*1502 testing is recommended in patients of Asian ancestry before carbamazepine (covered in 11.4). Management: stop the offending drug, supportive care in a burn unit.
Drug reaction with eosinophilia and systemic symptoms (DRESS) — delayed (2–8 weeks), rash, fever, lymphadenopathy, eosinophilia, hepatitis, and visceral involvement. Culprits: aromatic anticonvulsants (phenytoin, carbamazepine, phenobarbital), allopurinol, sulfonamides, dapsone, minocycline, vancomycin . Treatment: stop the drug, systemic corticosteroids.
Acute generalized exanthematous pustulosis (AGEP) — rapid onset (<4 days) of sterile nonfollicular pustules on an erythematous base, fever, leukocytosis. Culprits: beta-lactams (especially aminopenicillins), macrolides, diltiazem, terbinafine . Self-limited after drug discontinuation.
Musculoskeletal Toxicity
Fluoroquinolones carry an FDA warning for tendinopathy and tendon rupture (Achilles most common), muscle weakness and exacerbation of myasthenia gravis , CNS effects , and QT prolongation . Risk increases with corticosteroid co-administration and age >60. Glucocorticoids and chronic PPI use (≥1 year) increase osteoporosis and fracture risk; calcium, vitamin D, and bisphosphonate prophylaxis may be warranted. Statins cause myalgia, myositis, and rare rhabdomyolysis (higher with high-dose statins, gemfibrozil co-administration, and certain CYP interactions).
- Drug Use Disorders
- DSM-5 Framework
DSM-5 unifies substance use disorders on a single spectrum from mild (2–3 criteria) , moderate (4–5) , to severe (6+) over a 12-month period. The 11 criteria include hazardous use, social/interpersonal problems, neglect of major roles, tolerance, withdrawal, larger/longer use than intended, repeated attempts to cut down, much time spent using, physical/psychological problems caused by use, activities given up, and craving . Tolerance and withdrawal alone do not define a disorder for patients on prescribed medications.
Opioid Use Disorder (OUD)
Medications for Addiction Treatment (MAT) — formerly known as medication-assisted treatment — combine pharmacotherapy with counseling:
Buprenorphine (partial μ agonist, ceiling on respiratory depression): office-based via DEE X-waiver (post-MAT Act, no separate waiver required but training recommended); formulations include sublingual, subdermal implant, monthly Sublocade injection.
Methadone (full μ agonist): only via federally regulated Opioid Treatment Programs (OTPs) for OUD; useful for severe dependence and chronic pain with OUD.
Naltrexone (μ antagonist): only after 7–10 days opioid-free to avoid precipitated withdrawal; monthly Vivitrol injection.
Naloxone (antagonist for overdose reversal): intranasal or IM; co-prescribed with opioids for overdose prevention; standing orders in many states.
Sedative/Hypnotic and Anxiolytic Use Disorder
Benzodiazepines carry tolerance, dependence, and withdrawal risks. Withdrawal can be life-threatening (seizures, delirium). Management: long taper (10% per week or slower) , switch to a long-acting agent (diazepam, clonazepam) for smoother taper, phenobarbital or low-dose buprenorphine protocols in supervised settings. Avoid combining benzodiazepines with opioids (additive respiratory depression — boxed warning).
Stimulant Use Disorder
Stimulant use disorder (cocaine, methamphetamine, prescription amphetamines) has no FDA-approved pharmacotherapy . Treatment is behavioral — contingency management (strongest evidence), CBT , motivational interviewing , and Matrix Model for methamphetamine. Treat comorbid conditions (depression, ADHD) appropriately.
Cannabis Use Disorder
Cannabis use disorder is increasingly recognized with legalization. Withdrawal includes irritability, anxiety, sleep disturbance, and appetite loss. No FDA-approved pharmacotherapy; CBT and motivational enhancement therapy are first-line. Synthetic cannabinoids (K2, Spice) carry greater toxicity.
Tobacco Use Disorder
Three first-line FDA-approved pharmacotherapies :
Nicotine Replacement Therapy (NRT) : patches (long-acting baseline) + short-acting (gum, lozenge, inhaler, nasal spray) for breakthrough cravings; combination NRT is more effective than monotherapy.
Varenicline : α4β2 nicotinic receptor partial agonist — generally most effective monotherapy; reduce dose with renal impairment; neuropsychiatric warnings softened by EAGLES trial data but still monitored.
Bupropion SR : norepinephrine-dopamine reuptake inhibitor; avoid in eating disorders, seizure disorders, and with MAOIs; start 1–2 weeks before quit date.
Second-line: clonidine , nortriptyline . Combine pharmacotherapy with behavioral counseling (5 A's: Ask, Advise, Assess, Assist, Arrange).
Harm Reduction and Structural Controls
Harm reduction meets patients where they are: syringe exchange programs reduce HIV/HCV transmission and link to treatment; supervised consumption sites reduce overdose mortality; fentanyl test strips and xylazine awareness inform risk; naloxone distribution (standing orders, pharmacy access, co-prescribing with opioids) reverses overdose. REMS programs — ER/LA opioid REMS (prescriber education), TIRF REMS (immediate-release fentanyl restricted to opioid-tolerant patients), transmucosal buprenorphine REMS (now merged with broader MAT training). Prescription Drug Monitoring Programs (PDMPs) are state-run databases tracking controlled substance prescriptions; pharmacists query them to identify multiple prescribers, early refills, and drug combinations suggestive of misuse.
Misuse, Abuse, Diversion, and Pseudoaddiction
Misuse = use for a medical purpose but in a manner other than prescribed. Abuse = use for non-medical purposes or recreational effects. Diversion = transfer of a controlled substance from the lawful distribution chain to an unlawful one (doctor shopping, forgery, theft, internet pharmacies). Pseudoaddiction describes behavior that mimics addiction (demanding higher doses, clock-watching) but is driven by inadequately treated pain ; the behavior resolves when pain is adequately managed — a key concept to distinguish from true opioid use disorder.